L1-Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles

Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Deno P. Dialynas, Zou Quan, Katherine A. Wall et al. · The Journal of Immunology · 1983 · 1.3K citations

Life Sciences, Cell Biology, Immunology +12

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Reinhard Kirnbauer, Frank P. Booy, N. Cheng et al. · Proceedings of the National Academy of Sciences · 1992 · 1.1K citations

Life Sciences, Immunology, Molecular Biology +17

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

K Y Lin, Frank Guarnieri, Kevin F. Staveley-O’Carroll et al. · PubMed · 1996 · 1K citations

Medicine, Immunology, Oncology +17

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

Mariet C.W. Feltkamp, Henk L. Smits, Michel Vierboom et al. · European Journal of Immunology · 1993 · 838 citations

Medicine, Immunology, Oncology +17

IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

M Sarmiento, Andrew L. Glasebrook, Frank W. Fitch · The Journal of Immunology · 1980 · 817 citations

Life Sciences, Biochemistry, Immunology +12